Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two companies in the weight loss market right now. They are both raking in billions in revenue from their glucagon-like peptide-1 (GLP-1) drugs. But given how lucrative the market is -- one estimate says it will be worth $100 billion by 2030 -- you can be sure that there will be a lot of competition.
In fact, several small, up-and-coming healthcare companies are developing GLP-1 weight loss drugs in the hopes of striking it big in the anti-obesity drug market.
Yet, the immediate and bigger concern for Novo Nordisk and Eli Lilly may be competition from larger and more established healthcare companies.
Source Fool.com
